Today, Cancer Treatment Centers of America announced a new partnership with MedAllies to help keep providers informed about the new CoP notification requirements from the Centers for Medicare & Medicaid Services.
Boca Raton, FL., August 31, 2021— When the Centers for Medicare & Medicaid Services (CMS) added a new Condition of Participation (CoP) requiring hospitals to send electronic patient event notifications to alert primary care providers and post-acute care providers of a patient’s admission, discharge, or transfer to another healthcare facility, Cancer Treatment Centers of America® (CTCA) took it several steps further. They built new technology that not only complied with the requirement by the deadline of May 1, 2021, but also is poised to expand its capabilities to engage with referring providers.
In partnership with MedAllies, a leading national interoperable network and Health Information Service Provider (HISP), CTCA leveraged its own systems to connect with the MedAllies HISP platform and created an innovative proprietary technological solution to meet the CoP notification requirements. Utilizing its Patient Notification Hub, which streams real-time patient events into a centralized location, CTCA partnered with MedAllies to build a solution that subscribes to any event included in CoP notification requirements. Through the Patient Notification Hub, the solution seamlessly sends event notifications securely in real-time to patients’ known providers. Leveraging cloud-native serverless infrastructure, this event sourcing solution can easily be enhanced to meet changing needs within the healthcare industry and can be adapted when legislative changes require adding or removing event types.
“Through technological innovation that keeps referring providers informed at an event level, we enhance the personalized patient-centered approach to care that CTCA is committed to delivering,” said CTCA Chief Information Officer, Jennifer Greenman.
Building upon this solution, CTCA is aiming to integrate the Patient Notification Hub with its recently released Provider Portal. Utilizing the Provider Portal, referring providers within the CTCA network can easily refer patients and receive updates on all clinically relevant information and patient events. At its core, the Provider Portal creates efficiency in the referral process and enhances communication and collaboration between patients’ CTCA care teams and referring providers.
“MedAllies is honored to partner with a world-class organization like CTCA by providing a component of their recent innovation to address this CoP mandate and set the stage for them to deliver additional capabilities to their care teams,” said MedAllies Chief Commercial Officer, Tom Visotsky.
About Cancer Treatment Centers of America
Cancer Treatment Centers of America® (CTCA) is a national oncology network of hospitals and outpatient care centers offering an integrated approach that combines surgery, radiation, chemotherapy, immunotherapy and advancements in precision medicine with supportive therapies to manage side effects and enhance quality of life during treatment and into survivorship. CTCA® publishes treatment results bi-annually including patient experience, length of life, quality of life, patient safety and quality of care. CTCA also offers qualified patients a range of clinical trials that may reveal new treatment options supported by scientific and investigational research. CTCA patient satisfaction scores consistently rank among the highest for all cancer care providers in the country. Visit cancercenter.com for more information.
About MedAllies
MedAllies securely delivers vital health information to impact care by operating a nationwide interoperable network supporting all healthcare constituents. We are focused on optimizing the adoption and usage of healthcare interoperability for the people, systems and services connected to our MedAllies network, eliminating information care gaps and fostering a truly interoperable and connected future. We serve more than 700 hospitals, 100,000 providers and dozens of vendor partners bringing together millions for a more fluid healthcare experience. Learn more at medallies.com.
++++
Media contact:
Samantha Paz
215-537-7080
Samantha.Paz@ctca-hope.com
Does Odronextamab Show Hope in FL and DLBCL Despite Regulatory Hurdles?
November 5th 2024Despite regulatory challenges from the FDA, odronextamab has received European approval for the treatment of patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma following 2 prior treatments.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
TMLI Trial Shows Potential in Relapsed/Refractory Leukemia
October 2nd 2024In an interview, Jeffrey Wong, MD, and Anthony Stein, MD, provided an in-depth discussion on a phase 2 trial of total marrow and lymphoid irradiation with cyclophosphamide and etoposide in high-risk acute leukemia.
Read More